For Helen and Lee Draper, the transition to university was supposed to be a milestone of independence and excitement for their 18-year-vintage daughter, Meg. Instead, it became the backdrop for a rapid medical collapse that has left them campaigning to close a critical gap in the United Kingdom’s public health shield.
Meg, described by her parents as a popular and sporty teenager, died from Meningitis B (MenB) in October 2025 even as studying at the University of Bournemouth. Her death has sparked a poignant and urgent plea from her parents for a wider rollout of the MenB vaccine to teenagers and young adults, arguing that the current NHS eligibility criteria abandon a dangerous segment of the population vulnerable.
The tragedy is compounded by a series of medical missed opportunities. Before her death, Meg was turned away from the Royal Bournemouth Hospital A&E on two separate occasions, despite exhibiting classic symptoms of a life-threatening infection. The Drapers now argue that the combination of clinical oversight and a restrictive vaccination policy creates a “fatally flawed” system where the burden of survival rests on the ability of parents to challenge medical professionals.
Helen and Lee said they were not aware of a MenB vaccine before Meg died [Meg Draper]
A Timeline of Systemic Failure
The decline happened with terrifying speed. After reporting feelings of lethargy, Meg’s condition deteriorated within 24 hours, manifesting as fever, headache, vomiting, and a characteristic rash. When a friend took her to the Royal Bournemouth Hospital A&E, the Drapers say a triage nurse selected “no” on a computer screen when prompted about sepsis, resulting in Meg being sent back to her university accommodation.
The situation grew more dire. Helen and Lee drove from South Wales to Bournemouth to personally escort their daughter back to the hospital. Despite Meg being visibly confused and unable to remember her date of birth—a significant neurological red flag—Helen recalls the attending physician being “curt” and frustrated. The doctor dismissed the symptoms as “nothing sinister” and advised the family to return home and rest.
Driven by a lingering sense of dread, the family began the journey back to Wales. However, Meg’s condition worsened during the trip, leading to her admission to Southmead Hospital in Bristol, where she ultimately passed away. A spokesperson for the University Hospitals Dorset NHS Foundation Trust stated that while their thoughts are with the family, they cannot comment further pending the results of the inquest into Meg’s death.
The Vaccination Gap: MenACWY vs. MenB
As a physician, I often encounter confusion regarding the different types of meningitis vaccines. The tragedy of Meg’s case highlights a specific policy divide in the NHS. Meg had been vaccinated against meningitis strains A, C, W, and Y (MenACWY) at age 14, as per the standard NHS schedule. However, the MenB vaccine—which targets a different strain of the bacteria—is only routinely offered to young children born after May 2015.
While MenB is relatively rare in children over the age of four, epidemiological data shows a second, distinct peak in incidence among teenagers and young adults. Despite this, the Joint Committee on Vaccination and Immunisation (JCVI) concluded in 2014 that expanding the MenB vaccine to this age group was “not cost effective.” For those outside the infant eligibility window, the vaccine must be purchased privately, costing approximately £220.
| Vaccine Type | NHS Eligibility | Target Strains |
|---|---|---|
| MenACWY | Free for teenagers in England and Wales | A, C, W, Y |
| MenB | Free for children born after May 2015 | B |
| Private MenB | Available for purchase (approx. £220) | B |
Outbreaks and Political Pressure
The Drapers’ campaign has gained urgency following an “unprecedented” outbreak of MenB in Kent, which resulted in the deaths of two young people: a 21-year-old University of Kent student and Juliette, a sixth-form pupil at Queen Elizabeth’s Grammar School in Faversham. This cluster of cases has forced a government re-evaluation of the status quo.
UK Health Secretary Wes Streeting has since asked the JCVI to revisit its 2014 decision and provide “fresh advice” on eligibility for teenagers and young adults. Streeting stated that he intends to follow the committee’s updated guidance.
Political pressure is mounting in Wales as well. Spokespeople from the Welsh Liberal Democrats, Plaid Cymru, and the Welsh Conservatives have all urged the government to act swiftly if medical evidence suggests that extending vaccine access would prevent further preventable tragedies.
The Danger of ‘Misinformation’
Beyond the policy gap, the Drapers are highlighting a failure in communication. In the weeks following Meg’s death, the University of Bournemouth’s on-campus GP held three vaccination clinics. However, the vaccines provided were for the MenACWY strains, not MenB.
Helen Draper describes this as “dangerous misinformation,” noting that students may have left those clinics believing they were fully protected against the strain that killed their peer. The University of Bournemouth responded that its medical centre was unable to provide the MenB vaccine but emphasized that MenACWY is a life-saving tool. The university has since updated its guidance to ensure students are clear about the differences between the vaccines.
Helen and Lee said Meg was turned away by A&E twice before she died [Helen and Lee Draper]
The UK Health Security Agency (UKHSA) maintains that its guidance is clear. Dr. Mary Ramsay, Deputy Director of Public Health Programmes at UKHSA, emphasized that neither the infant MenB vaccine nor the teenage MenACWY vaccine protects against all meningococcal strains. She urged parents of children born before May 2015 to consult their GP regarding MenB protection.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare provider for vaccination guidance and diagnosis.
The next critical checkpoint in this effort will be the release of the JCVI’s updated advice to the UK government. Whether the committee shifts its stance on “cost-effectiveness” in favor of broader protection will determine if thousands of university students remain unprotected against strain B.
We want to hear from you. Do you believe the NHS should expand MenB eligibility to university students? Share your thoughts in the comments below.
